Baillie Gifford & CO Summit Therapeutics Inc. Call Options Transaction History
Baillie Gifford & CO
- $111 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$484 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$231 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$157 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$130 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$96.2 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.99B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...